10-QPeriod: Q3 FY2025

CARDINAL HEALTH INC Quarterly Report for Q3 Ended Mar 31, 2025

Filed May 1, 2025For Securities:CAH

Summary

Cardinal Health Inc. reported its third-quarter fiscal year 2025 results, demonstrating resilience despite revenue being flat year-over-year at $54.9 billion. This stability was achieved despite the prior-year impact of the OptumRx contract expiration, which was offset by growth in branded and specialty pharmaceutical sales. The company saw a significant increase in GAAP operating earnings, up 98% to $730 million, and a 21% increase in non-GAAP operating earnings to $807 million, driven by contributions from branded/specialty pharmaceuticals, cost savings initiatives, and MSO acquisitions. These improvements were partially tempered by the ongoing impact of the OptumRx contract expiration. Key strategic developments include substantial acquisitions in the healthcare services space, notably the $2.8 billion acquisition of GI Alliance (GIA) and the $1.1 billion acquisition of Advanced Diabetes Supply Group (ADSG), which are expected to bolster the Pharma and Other segments, respectively. While these acquisitions increase debt and acquisition-related costs, they signal a clear strategy to expand into higher-growth areas. The company's liquidity remains strong, supported by operating cash flow and credit facilities, though long-term debt has increased to fund these strategic investments. Investors should monitor the integration of these acquisitions and the continued impact of the OptumRx contract loss on future performance.

Financial Highlights

47 data points
Beta

Revenue

$54.88B

3.9% Gross Margin

Net Income

$506.00M

0.9% Net Margin

Total Assets

$49.87B

Cash & Equivalents

$3.33B

Free Cash Flow

$2.79B

Financial Statements
Beta
Revenue$54.88B
Cost of Revenue$52.76B
Gross Profit$2.12B
SG&A Expenses$1.31B
Operating Income$730.00M
Interest Expense$74.00M
Net Income$506.00M
Shares Outstanding (Basic)240.00M
Shares Outstanding (Diluted)241.00M

Key Highlights

  • 1Revenue remained flat at $54.9 billion for the third quarter, demonstrating stability despite headwinds from the OptumRx contract expiration.
  • 2GAAP operating earnings surged by 98% to $730 million, and non-GAAP operating earnings increased by 21% to $807 million, driven by strong performance in pharmaceuticals and strategic acquisitions.
  • 3Significant strategic investments were made, including the $2.8 billion acquisition of GI Alliance and the $1.1 billion acquisition of Advanced Diabetes Supply Group, signaling a focus on expanding healthcare services and at-home solutions.
  • 4Long-term debt increased to $7.7 billion from $5.1 billion, largely to fund recent acquisitions, impacting the company's leverage profile.
  • 5Net cash provided by operating activities was $870 million for the first nine months, which included significant payments related to opioid litigation ($797 million).
  • 6The company announced a definitive agreement to acquire Urology America, further expanding its presence in the urology market.
  • 7Shareholder returns remain a focus, with $374 million deployed for cash dividends and $750 million for share repurchases during the nine-month period.

Frequently Asked Questions

The expiration of the OptumRx contracts in June 2024 had an adverse impact on revenue and segment profit, particularly in the Pharmaceutical and Specialty Solutions segment. While these contracts represented 17% of consolidated revenue in fiscal 2024, they generated a lower operating margin. The company has been working to offset this impact through new customer onboarding, growth from existing customers, and cost savings measures, but expects some adverse effects to continue through fiscal 2025.

The acquisitions of GI Alliance (GIA) for $2.8 billion and Advanced Diabetes Supply Group (ADSG) for $1.1 billion represent significant strategic investments expected to positively impact segment revenue and profit. However, these acquisitions also contributed to an increase in long-term debt and will lead to higher amortization and acquisition-related costs in the near term. GIA results are consolidated within the Pharma segment, while ADSG will be part of the at-Home Solutions operating segment.

Cardinal Health funded the GIA and ADSG acquisitions through a combination of cash on hand and $2.9 billion in new debt financing. This has increased total long-term obligations to $7.7 billion. The company maintains a $3.0 billion commercial paper program and has revolving credit facilities available, with no amounts outstanding as of March 31, 2025. They were in compliance with their consolidated net leverage ratio covenant of no more than 3.75-to-1 as of March 31, 2025.

Cardinal Health has accrued $4.9 billion as of March 31, 2025, for opioid litigation settlements. They have paid approximately $1.9 billion to settling governmental entities under the National Opioid Settlement Agreement through April 2025, with additional payments expected through 2038. The company has also settled claims with the City of Baltimore and other private plaintiffs, including classes of third-party payors and acute care hospitals. While the company disputes the allegations, these settlements represent a significant ongoing financial commitment.